Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors
Work
Year: 2025
Type: article
Abstract: Background There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with ... more
Source: JNCI Cancer Spectrum
Institutions University of Washington, Fred Hutch Cancer Center, Kaiser Permanente, Kaiser Permanente Washington Health Research Institute, VA Office of Research and Development +3 more
Cites:
Cited by:
Related to: 10
FWCI:
Citation percentile (by year/subfield):
Subfield: Genetics
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $1,236